公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2020 | Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases | CHIH-HSIN YANG ; Schuler M.; Popat S.; Miura S.; Heeke S.; Park K.; Märten A.; Kim E.S. | Journal of Thoracic Oncology | 175 | 156 | |
2015 | Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 | CHIH-HSIN YANG ; Sequist L.V.; Geater S.L.; Tsai C.-M.; Mok T.S.K.; Schuler M.; Yamamoto N.; CHONG-JEN YU ; Ou S.H.I.; Zhou C.; Massey D.; Zazulina V.; Wu Y.-L. | The Lancet Oncology | 778 | 644 | |
2020 | Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts | Bang Y.-J.; Su W.-C.; Schuler M.; Nam D.-H.; Lim W.T.; Bauer T.M.; Azaro A.; Poon R.T.P.; Hong D.; CHIA-CHI LIN ; Akimov M.; Ghebremariam S.; Zhao S.; Giovannini M.; Ma B. | Cancer Science | 43 | 35 | |
2013 | Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations | Sequist L.V; CHIH-HSIN YANG ; Yamamoto N; O'Byrne K; Hirsh V; Mok T; Geater S.L; Orlov S; Tsai C.-M; Boyer M; Su W.-C; Bennouna J; Kato T; Gorbunova V; Lee K.H; Shah R; Massey D; Zazulina V; Shahidi M; Schuler M. | Journal of Clinical Oncology | 2727 | 2366 | |
2021 | Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study | Subbiah V.; Hu M.I.; Wirth L.J.; Schuler M.; Mansfield A.S.; Curigliano G.; Brose M.S.; Zhu V.W.; Leboulleux S.; Bowles D.W.; Baik C.S.; Adkins D.; Keam B.; Matos I.; Garralda E.; Gainor J.F.; Lopes G.; CHIA-CHI LIN ; Godbert Y.; Sarker D.; Miller S.G.; Clifford C.; Zhang H.; Turner C.D.; Taylor M.H. | The Lancet Diabetes and Endocrinology | 187 | 140 |